SynthesisEuropean journal of clinical pharmacology1997
The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis.
Synthesis in European journal of clinical pharmacology, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- CYP2D6 T188C variant is associated with lung cancer risk in the Chinese population.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013Pooled it
- Impact of genetic notification on smoking cessation: systematic review and pooled-analysis.PloS one · 2012Pooled it
- Untangling SNP Variations withinJournal of personalized medicine · 2022Article
- Article
- Genetic polymorphisms of phase I and phase II metabolic enzymes as modulators of lung cancer susceptibility.Journal of cancer research and clinical oncology · 2015Article
- Contributions of human enzymes in carcinogen metabolism.Chemical research in toxicology · 2012Review
- Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.Naunyn-Schmiedeberg's archives of pharmacology · 2004Review
- Polymorphic cytochromes P450 and drugs used in psychiatry.Cellular and molecular neurobiology · 1999Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo examine the association between the sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer.
methodMeta-analysis of case-control studies using a random effects model. The "Main outcome measure" was the odds ratio for the risk of lung cancer, using extensive metabolisers as the reference group.
resultsThirteen studies were identified. The studies were too heterogeneous to be pooled the size of the odds ratio increased with the sample size. When the analysis was restricted to the largest studies, there was no difference in risk between poor and extensive metabolisers (odds ratio 0.95, 95% confidence interval 0.68-1.33).
conclusionNo association was found between the CYP2D6 oxidation polymorphism and lung cancer risk when sample size bias was taken into account.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.